Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

HISTORICAL FACTS: Hc wainwright reiterates buy rating on biontech while lowers price target - The Untold Story

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ:BNTX) while reducing the price target to $298 from the prior $339.

The analyst noted initial data of BNT211, an autologous CAR-T cell therapy, shared at the American Association for Cancer Research (AACR) meeting.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.